Weekly Doxorubicin with Tegafur-Uracil Slowed Progression of Metastatic Hepatocelluar Carcinoma in Schizophrenia Patients

We herein reported on 2 schizophrenia patients comorbid with metastatic hepatocellular carcinoma (HCC) who received palliative chemotherapy using weekly doxorubicin (30 mg/m^2 on day 1, day 8 and day 15 every 4 weeks) and tegafur-uracil (400 mg/day, 5 days every week). After 6 months of treatment, the metastatic HCC responded favorably to treatment and reached a stable disease status (according to the World Health Organization criteria), and survival extended over 18 months for both patients. The chemotherapy toxicity was well-tolerated and psychotic symptoms were controlled throughout the treatment period. Close cooperation between oncologist and psychiatrist is helpful to most effectively pursue the chemotherapy schedule and obtain survival benefit. This combination chemotherapy could be a treatment alternative for metastatic HCC in schizophrenia patients who were unsuitable for Sorafenib use.